ClinicalTrials.gg
RecruitingNCT04800393TeMPUpdated Apr 26, 2023

The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.

An interventional study of Sevoflurane and Propofol in Anesthesia and Breast Cancer, sponsored by Moscow Clinical Scientific Center. Recruiting at 1 site in Russian Federation. Open to female participants aged 45 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-04-26.

Sponsored by Moscow Clinical Scientific Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
45 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies in Breast Neoplasms with a site in Russian Federation — 9 open to participants now, 10 under way, 1 of them phase 3. Breast Neoplasms · Russian Federation.

Planned enrollment
117th of 166
130 · median 334
Started
2022
with 6 others
No phase
7 of 180
4 open now
Registered
166th of 180
by date

Among the 180 studies in Breast Neoplasms with a site in Russian Federation, this one is the 117th largest by planned enrollment of the 166 interventional ones that give a count, is one of 7 that started in 2022, is one of 7 with no phase, and was the 166th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 180 studies in Breast Neoplasms with a site in Russian Federation are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 45 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Breast Neoplasms with a site in Russian Federation, or all of them as a file.
02

Study summary

Even decade ago it was believed that the choice method of anesthesia did not affect the course of the oncological process, but recent evidence has begun to emerge that inhalation anesthesia vs TIVA is associated with a higher number of adverse outcomes. Apparently, it makes sense to conduct mRCT in order to assess the effect of IA on immune system in patients operated on for breast cancer comprehensively. The results of that kind of RCT may finally give us an answer whether the choice of anesthesia affects the immune status of patients undergoing surgery for breast cancer. The evaluation of complications and long-term survival will allow to recommend to use or not to use IA for this type of surgery.

Objective: The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery

Read the detailed description

The power calculation for this study was based on an assessment of Neutrophil-lymphocyte ratio (NLR) in patients undergoing breast cancer resection with total intravenous and inhalation anesthesia in two studies:

  1. Cho J.S. et al., 2017 - 48 patients (PMID: 28924368, TIVA group: NLR = 3.37 ± 1.27; inhalation group: NLR = 3.85 ± 1.46)
  2. Ní Eochagáin A. et al., 2018 - 116 patients (PMID: 29457215, TIVA group: NLR = 3.20 ± 1.37; inhalation group: NLR = 4.10 ± 1.90).

The pooled mean NLR in the TIVA group is 3.25±1.34, in the inhalation anesthesia group: 4.03±1.78.

Difference in means (effect size): 0.78, for level α=0.05, power 1-β=80% and expected standard deviation of 1.5, 65 patients in each group should be recruited, taking into account a 10% margin (total number of patients: 130).

03

Conditions studied

  • Anesthesia
  • Breast Cancer

Keywords

  • Anesthesia
  • Breast Cancer
  • Phagocyte Cell Dysfunction
  • Immune Suppression
  • Inhalation anesthesia
  • volatile anesthesia
  • total intravenous anesthesia
  • interleukins
  • phagocytosis
  • neutrophil-lymphocyte ratio
  • natural killers
  • oncology
04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The age of the patients is from 45 to 74 years;
  • Primary operable breast cancer (BC) without prior chemotherapy;
  • confirmed breast malignant tumor of IA-IIA stages (T1-2, N0, M0);
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Acute cerebrovascular accident (CVA) occurred in the previous 6 months;
  • Myocardial infarction (MI) occurred in the previous 6 months;
  • Acute arterial thrombosis occurred in the previous 6 months;
  • Acute venous thromboembolism occurred in the previous 6 months;
  • Subarachnoid hemorrhage occurred during the previous 3 months;
  • Chronic kidney disease (CKD) stage 3B-5;
  • Сhronic heart failure () class 3-4;
  • Pregnancy;
  • History of another location cancer;
  • History of drug addiction;
  • diseases in history;
  • Post-randomization: withdrawal of (refusal to continue participating in the study);
  • Post-randomization: surgical intervention, performed not in full (verified non-resected lesions in the early p/o period, 2 weeks p/o).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Inhalation anesthesia

    Drug: Sevoflurane

  • Active comparator
    Total intravenous anesthesia

    Drug: Propofol

Interventions

  • induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery

  • propofol-based total intravenous anesthesia during breast cancer surgery

06

What researchers measure

Primary outcomes

  1. Neutrophil-lymphocyte ratio

    Absolute number of neutrophils divided by the absolute number of lymphocytes

    Time frame: 1 hour after surgery

  2. Neutrophil-lymphocyte ratio

    Absolute number of neutrophils divided by the absolute number of lymphocytes

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Matrix metallopeptidase 9

    ng/mL

    Time frame: 1 hour after surgery

  2. Matrix metallopeptidase 9

    ng/mL

    Time frame: 24 hour after surgery

  3. C-reactive protein

    mg/L

    Time frame: 1 hour after surgery

  4. C-reactive protein

    mg/L

    Time frame: 24 hour after surgery

  5. Natural killer cells of blood (CD3-CD16 +)

    Absolute number (х 10\^9 /L)

    Time frame: 1 hour after surgery

  6. Natural killer cells of blood (CD3-CD16 +)

    Absolute number (х 10\^9 /L)

    Time frame: 24 hour after surgery

  7. Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)

    the ratio of T helper cells to cytotoxic T cells

    Time frame: 1 hour after surgery

  8. Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)

    the ratio of T helper cells to cytotoxic T cells

    Time frame: 24 hour after surgery

  9. IL-6

    pg/ml

    Time frame: 1 hour after surgery

  10. IL-6

    pg/ml

    Time frame: 24 hour after surgery

Other outcomes

  1. T cells of blood (CD3 +)

    Absolute number (х 10 /L)

    Time frame: 1 hour after surgery

  2. T cells of blood (CD3 +)

    Absolute number (х 10\^9 /L)

    Time frame: 24 hours after surgery

  3. T helpers of blood (CD3 + CD4 +)

    Absolute number (х 10\^9 /L)

    Time frame: 1 hour after surgery

  4. T helpers of blood (CD3 + CD4 +)

    Absolute number (х 10\^9 /L)

    Time frame: 24 hours after surgery

  5. Cytotoxic T cells of blood (CD3 + CD8 +)

    Absolute number (х 10\^9 /L)

    Time frame: 1 hour after surgery

  6. Cytotoxic T cells of blood (CD3 + CD8 +)

    Absolute number (х 10\^9 /L)

    Time frame: 24 hours after surgery

  7. B cells of blood (CD19 + CD3-)

    Absolute number (х 10\^9 /L)

    Time frame: 1 hour after surgery

  8. B cells of blood (CD19 + CD3-)

    Absolute number (х 10\^9 /L)

    Time frame: 24 hour after surgery

  9. T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood

    percentage

    Time frame: 1 hour after surgery

  10. T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood

    percentage

    Time frame: 24 hours after surgery

  11. Phagocytosis

    percentage

    Time frame: 1 hour after surgery

  12. Phagocytosis

    percentage

    Time frame: 24 hours after surgery

  13. IgA

    g/L

    Time frame: 1 hour after surgery

  14. IgA

    g/L

    Time frame: 24 hours after surgery

  15. IgM

    g/L

    Time frame: 1 hour after surgery

  16. IgM

    g/L

    Time frame: 24 hours after surgery

  17. IgG

    g/L

    Time frame: 1 hour after surgery

  18. IgG

    g/L

    Time frame: 24 hours after surgery

  19. Complement component C3

    g/L

    Time frame: 1 hour after surgery

  20. Complement component C3

    g/L

    Time frame: 24 hours after surgery

  21. Complement component C4

    g/L

    Time frame: 1 hour after surgery

  22. Complement component C4

    g/L

    Time frame: 24 hours after surgery

  23. Overall survival

    percentage of survival patients

    Time frame: 1 year

  24. Overall survival

    percentage of survival patients

    Time frame: 3 year

  25. Overall survival

    percentage of survival patients

    Time frame: 5 year

  26. Disease-free survival

    percentage of survival patients

    Time frame: 1 year

  27. Disease-free survival

    percentage of survival patients

    Time frame: 3 year

  28. Disease-free survival

    percentage of survival patients

    Time frame: 5 year

07

Study locations

1 of 1 sites recruiting
  • Moscow Scientific Clinical Center
    Moscow, 111123, Russian Federation
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2023, 15 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 15 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Mar 16, 2021
StartActual
Mar 29, 2022
Primary completionEst.
Jul 1, 2023
CompletionEst.
Apr 1, 2028
Last update
Apr 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04800393
Lead sponsor
Moscow Clinical Scientific Center
Collaborators
Negovsky Reanimatology Research Institute
Responsible party
Valerii Subbotin (PhD, Moscow Clinical Scientific Center) — Principal investigator
First posted
Mar 16, 2021
Start date
Mar 29, 2022
Primary completion
Jul 1, 2023 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Apr 26, 2023

Study contacts

Valerii Subbotin, PhD
Contact
subbotin67@mail.ru
+79166122504
Kristina Kadantseva
Contact
kristina161093@gmail.com
+79168306947
Valerii Subbotin, PhD
principal investigator · Moscow Scientific Clinical Center
Valery Likhvantsev, PhD
study director · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevoflurane

Start the discussion